[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial
Conclusion: Long-term outcomes with [177Lu]Lu-PSMA-617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Satapathy, S., Mittal, B. R., Sood, A., Das, C. K., Mavuduru, R. S., Goyal, S., Shukla, J., Singh, S. K. Tags: Brief Communications Source Type: research
Prediction of Resistance to 177Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers
Conclusion: Our analyses indicate that ctDNA assays may contain specific biomarkers predictive of response or resistance for 177Lu-PSMA–treated mCRPC patients. Additional confirmatory studies are required before clinicians can use these findings to make personalized treatment decisions. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Sartor, O., Ledet, E., Huang, M., Schwartz, J., Lieberman, A., Lewis, B., Layton, J., Barata, P., Jang, A., Hawkins, M., Pocha, O., Lanka, S., Harris, K. Tags: Brief Communications Source Type: research
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
Conclusion: 68Ga-FAPI PET/CT is a promising imaging probe that has a significant impact on TNM stage and clinical management. 68Ga-FAPI PET/CT promises to be a crucial new technology that will improve on conventional radiologic imaging methods such as contrast-enhanced CT and contrast-enhanced MRI typically acquired for cancer staging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Koerber, S. A., Rohrich, M., Walkenbach, L., Liermann, J., Choyke, P. L., Fink, C., Schroeter, C., Spektor, A.-M., Herfarth, K., Walle, T., Calais, J., Kauczor, H.-U., Jaeger, D., Debus, J., Haberkorn, U., Giesel, F. L. Tags: Clinical Investigations Source Type: research
Validation of the {Delta}SUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial
Conclusion: We recommend the use of the SUVmax alone rather than the Menton 2011 criteria for assessing the interim metabolic response in patients with diffuse large B-cell lymphoma, except when the baseline SUVmax is less than 10.0. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Itti, E., Blanc-Durand, P., Berriolo-Riedinger, A., Kanoun, S., Kraeber-Bodere, F., Meignan, M., Gat, E., Gouill, S. L., Casasnovas, R.-O., Bodet-Milin, C. Tags: Clinical Investigations Source Type: research
High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe detude des Tumeurs Endocrines and ENDOCAN-RENATEN Network
Conclusion: Tumor uptake on 18F-FDOPA PET/CT is an independent prognostic factor in patients with metastatic midgut NETs. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: De Rycke, O., Perrier, M., Ouvrard, E., Mennetrey, C., Lachachi, C., Bando-Delaunay, A., Morland, D., Goichot, B., Taieb, D., Walter, T., Cadiot, G., Cros, J., Hentic, O., Ruszniewski, P., Lebtahi, R., Imperiale, A., de Mestier, L. Tags: Clinical Investigations Source Type: research
18F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Gebhart, G. Tags: INVITED PERSPECTIVE Source Type: research
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
Conclusion: For the first time, we report a potential association between a C1D15 SULmax of 3 or less on 18F-FDG PET/CT and RFS and OS outcomes in patients with ER-negative, HER2-positive breast cancer receiving neoadjuvant HP alone. If confirmed in future studies, this imaging-based biomarker may facilitate early individualization of therapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Hennessy, M. A., Leal, J. P., Huang, C.-Y., Solnes, L. B., Denbow, R., Abramson, V. G., Carey, L. A., Liu, M. C., Rimawi, M., Specht, J., Storniolo, A. M., Valero, V., Vaklavas, C., Winer, E. P., Krop, I. E., Wolff, A. C., Cimino-Mathews, A., Wahl, R. L., Tags: Clinical Investigations Source Type: research
Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using 18F-FET PET
Conclusion: We proposed parametric 18F-FET PET as a noninvasive metabolic biomarker for the evaluation of CU characteristics, which differentiated IDH genotype with excellent diagnostic performance, establishing a critical association between spatial metabolic heterogeneity, mitochondrial tricarboxylic acid cycle, and genomic features with critical implications for clinical management and the diagnostic workup of patients with central nervous system cancer. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Lohmeier, J., Radbruch, H., Brenner, W., Hamm, B., Tietze, A., Makowski, M. R. Tags: Clinical Investigations Source Type: research
The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection
This article summarizes the resulting consensus, at least among the included scientists and countries, on the current status of radiopharmaceutical development for infection imaging. Also included are opinions and recommendations regarding current research standards in this area. This and future International Atomic Energy Agency–sponsored collaborations will advance the goal of providing the medical community with innovative, practical tools for the specific image-based diagnosis of infection. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Alberto, S., Ordonez, A. A., Arjun, C., Aulakh, G. K., Beziere, N., Dadachova, E., Ebenhan, T., Granados, U., Korde, A., Jalilian, A., Lestari, W., Mukherjee, A., Petrik, M., Sakr, T., Cuevas, C. L. S., Welling, M. M., Zeevaart, J. R., Jain, S. K., Wilson Tags: Focus on Molecular Imaging Source Type: research
FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Schmidkonz, C., Atzinger, A., Ramming, A., Kuwert, T. Tags: Hot Topics Source Type: research
Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Kairemo, K., Czernin, J. Tags: Discussions with Leaders Source Type: research
This Month in JNM
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Tags: This Month in JNM Source Type: research
Johan S. Masjhur, dr, SpPD-KEMD, SpKN-TM, 1942-2023
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Kartamihardja, H. S., Bailey, D. L. Tags: In Memoriam Source Type: research
Erratum
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Tags: Erratum Source Type: research
Addendum to MIRD Pamphlet No. 28
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Kesner, A. L., Carter, L. M., Bolch, W. E. Tags: Addendum Source Type: research
